Many people diagnosed with cancer have to take medications for years or indefinitely as part of their cancer treatment plan. Here, learn why long-term cancer medication might be prescribed for you and find 7 tips for managing the practical aspects of taking long-term medication.
In this “Voices on Cancer” post, Dr. Natasha Steele and Elle Billman share how their own cancer experiences led them to get involved with survivorship advocacy, how they’re working to build a community among cancer survivors, and what they’ve learned from other survivors along the way.
Dr. Richard A. Larson describes what people with cancer should know about blood transfusions, including why a blood transfusion might be needed during cancer, the different types of transfusions, what to expect during a transfusion, and possible side effects.
In this podcast, 2 Cancer.Net Associate Editors discuss new research presented at the 2023 ASCO Annual Meeting about preventing melanoma recurrence and reducing cancer disparities.
Leukemia survivor Lewis Christie shares what it was like undergoing 2 bone marrow transplants to treat his cancer, the challenges he faced during recovery, and how his life has changed after transplant.
Dr. Amar Kelkar and Dr. Vincent Ho discuss what people with cancer and their caregivers should know about recovery in the weeks and months after a bone marrow transplant, including what follow-up care will be needed, what symptoms may occur, and how daily life may change.
The ASCO Annual Meeting is being held June 2 to 6, and here is some of the notable research that will be presented today. Topics include treatment for anemia related to myelodysplastic syndromes, pembrolizumab for advanced cervical cancer, surgery options for early pancreatic cancer, weight loss in breast cancer survivorship, the effect of Medicare expansion on racial disparities, and collaborating across borders to help children with leukemia.
Read research from the February 2023 session of the ASCO Plenary Series, which highlights a study comparing 2 targeted therapy drugs for treating people with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
A study from China published in the Journal of Clinical Oncology has shown that CAR T-cell therapy that targets CD19 and CD22 is effective at treating recurrent or refractory acute lymphoblastic leukemia in children.
Dr. Craig A. Portell discusses what CAR T-cell therapy is, how it works, what its common side effects are, and how it’s changing the landscape of how some types of cancers are treated.
